3-(2,4-dimethoxybenzylidene)anabaseine has been researched along with Cognitive Decline in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amamiya, T; Ashihara, E; Ito, A; Kawanishi, S; Kem, WR; Kitade, T; Kitamura, R; Kitamura, Y; Kuroda, E; Mizoguchi, H; Nagasawa, T; Okamoto, H; Saito, Y; Shimohama, S; Sugino, Y; Takata, K; Takegami, S; Tawa, M; Toda, Y | 1 |
1 other study(ies) available for 3-(2,4-dimethoxybenzylidene)anabaseine and Cognitive Decline
| Article | Year |
|---|---|
Alpha7 nicotinic acetylcholine receptor-specific agonist DMXBA (GTS-21) attenuates Aβ accumulation through suppression of neuronal γ-secretase activity and promotion of microglial amyloid-β phagocytosis and ameliorates cognitive impairment in a mouse mode
Topics: alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Benzylidene Compounds; Brain; Cells, Cultured; Cognitive Dysfunction; Disease Models, Animal; Humans; Mice, Transgenic; Microglia; Neuroblastoma; Phagocytosis; Pyridines; Rats; Tumor Cells, Cultured | 2018 |